18 and older, any sex, with Solid Tumors. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Participants With Dose-limiting ToxicityPrimary· Up to completion of Cycle 1 (up to 28 days)
The Maximum Tolerated Dose and the development regimen of relacorilant with nab-paclitaxel was determined by the number of participants with dose-limiting toxicities as defined in the protocol.
Number of Participants With One or More Adverse Events Related to Treatment With RelacorilantSecondary· Up to 28 days after the last dose of study drug (Segment I: up to approximately 2.5 years, Segment II: up to approximately 1.5 years)
Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Objective response rate is defined by the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) as best response of complete response (CR) or partial response (PR) from the start of relacorilant or nab-paclitaxel, whichever is earliest, across all time points during study observation period (including both confirmed and unconfirmed responses).
Group
Value
95% CI
Segment I: Continuous Dosing Regimens
7
Segment II: Intermittent Dosing Regimens
2
Clinical Benefit RateSecondary· Up to 512 days
Clinical benefit rate is defined as the participants who have achieved CR or PR (including both confirmed and unconfirmed responses), or stable disease for 16 weeks or greater.
Group
Value
95% CI
Segment I: Continuous Dosing Regimens
13
Segment II: Intermittent Dosing Regimens
6
Duration of ResponseSecondary· From the time of response up to the last disease assessment (up to 512 days)
Duration of response (DOR) is defined as the date that criteria are met for CR or PR until the first date that progressive disease or death is objectively documented, whichever occurs first. Participants with no documentation of disease progression or death on-study are censored at the date of last available tumor assessment
Group
Value
95% CI
Segment I: Continuous Dosing Regimens
9.7
5.4 – 10.7
Segment II: Intermittent Dosing Regimens
NA
0.95 – NA
Progression-free SurvivalSecondary· Up to 512 days
Progression-free survival is defined as the time from date of first dose of relacorilant or nab-paclitaxel, whichever is earliest, to the date of documented disease progression per RECIST v1.1 or death for any cause, whichever occurs first. Participants with no documentation of disease progression or death on-study are censored at the date of last available tumor assessment.
Group
Value
95% CI
Segment I: Continuous Dosing Regimens
2.8
2.1 – 4.0
Segment II: Intermittent Dosing Regimens
3.7
2.9 – 16.2
Overall SurvivalSecondary· Up to 512 days
Overall survival is defined as the time from date of the first dose of relacorilant or nab paclitaxel, whichever is earliest, to the date of death for any cause. Participants with no documentation of death on-study are censored at the date at which they are last known to be alive.
Group
Value
95% CI
Segment I: Continuous Dosing Regimens
8.3
5.2 – 10.9
Segment II: Intermittent Dosing Regimens
16.5
8.5 – NA
Best Response Rate in Participants With Tumor Glucocorticoid Receptor (GR) Above or Below the Median Overall LevelSecondary· Up to 512 days
Best response is defined by RECIST v1.1 as the best response recorded from the date of the first dose of relacorilant or nab-paclitaxel, whichever is earliest, across all time points during study observation period (including both confirmed and unconfirmed responses).
Group
Value
95% CI
GR H-score Above the Overall Median
1
GR H-score Below the Overall Median
0
GR H-score Above the Overall Median
3
GR H-score Below the Overall Median
1
GR H-score Above the Overall Median
7
GR H-score Below the Overall Median
7
GR H-score Above the Overall Median
4
GR H-score Below the Overall Median
4
Pharmacokinetics: Area Under the Concentration-time Curve From Zero to 24 Hours (AUC0-24) of Plasma RelacorilantSecondary· Segment I: before dosing and up to 24 hours after dosing on Cycle 1 Day 8; Segment II: before dosing and up to 24 hours after dosing on Cycle 1 Day 1
Pharmacokinetics: AUC0-24 of Plasma Nab-PaclitaxelSecondary· Segment I: before dosing and up to 24 hours after dosing on Cycle 1 Day 8; Segment II: before dosing and up to 24 hours after dosing on Cycle 1 Day 1
Pharmacokinetics: Maximum Concentration (Cmax) of Plasma RelacorilantSecondary· Segment I: before dosing and up to 24 hours after dosing on Cycle 1 Day 8; Segment II: before dosing and up to 24 hours after dosing on Cycle 1 Day 1
Pharmacokinetics: Cmax of Plasma Nab-PaclitaxelSecondary· Segment I: before dosing and up to 24 hours after dosing on Cycle 1 Day 8; Segment II: before dosing and up to 24 hours after dosing on Cycle 1 Day 1
Time frame: Up to 28 days after the last dose of study drug (Segment I: up to approximately 2.5 years, Segment II: up to approximately 1.5 years).
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of this study was to assess the safety of the combination of relacorilant (CORT125134), a novel glucocorticoid receptor (GR) antagonist, and nab- paclitaxel in participants with solid tumors and to determine the preliminary efficacy of the combination of relacorilant and nab-paclitaxel. The structure for the study was a single arm, non-randomized, open- label, multicenter trial with no control group.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors
· recruiting
NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors
· Phase 1
· recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre
· Phase 3
· recruiting
NCT07395258 — A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Differe
· Phase 1
· recruiting
NCT07505069 — Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors
· EARLY_PHASE1
· recruiting
Other Corcept Therapeutics trials
Trials by the same sponsor.
NCT07240116 — Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects
· Phase 1
· completed
NCT06829537 — Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)
· completed
NCT06928779 — Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant
· Phase 1
· completed
NCT06495944 — Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants
· Phase 1
· completed
NCT05772169 — Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifep
· Phase 4
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Corcept Therapeutics
Last refreshed: 6 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02762981.